Serial use of urine multi-level pregnancy tests (MLPTs) has been shown to be a reliable and efficient strategy for excluding ongoing pregnancy after medical abortion at ≤ 63 days of gestation. This pilot project will assess whether MLPTs can enhance the quality of remote medical abortion services through enabling women to reliably ascertain their abortion outcomes at home sooner than would otherwise have been the case. safe2choose provides remote medical abortion services through the Internet (information, counselling and access to abortion pills) in a growing number of countries worldwide. safe2choose will collaborate with Gynuity Health Projects to pilot the utility of MLPTs for home follow-up as part of its remote medical abortion services. As safe2choose does not have a physical office, the location of the sponsor's office is listed in this entry as the study location. Women from the United States are NOT eligible to enroll.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion of women who successfully receive the MLPTs
Timeframe: 1 week after mailing the MLPTs
Proportion of women who use the MLPTs to determine their abortion outcome
Timeframe: 2 weeks after receiving medical abortion package
Proportion of women able to use MLPTs on their own without guidance or instruction from providers
Timeframe: 2 weeks after receiving medical abortion package
Proportion of women who take action based on the interpretation of their test results
Timeframe: 2 weeks after receiving medical abortion package
Proportion of women who are satisfied with using MLPTs
Timeframe: 2 weeks after receiving medical abortion package